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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
Primary objective
The primary objective is to assess the effectiveness of interventions to improve patient identiﬁcation, access to and utilisation of genetic
and genomic counselling services when compared to:
i) No intervention;
ii) Usual or current practice; and
iii) Other active intervention.
Secondary objective
The secondary objective is to explore the resource use and costs associated with interventions aimed at improving patient identiﬁcation,
access to and utilisation of genetic and genomic counselling services from studies meeting the eligibility criteria.
We will report on factors that may explain variation in the effectiveness of interventions aimed at improving patient identiﬁcation,
access to and utilisation of genetic and genomic counselling services from studies meeting the eligibility criteria.
Another secondary objective is to explore how interventions which target improved patient identiﬁcation, access to and utilisation of
genetic and genomic counselling services affect the subsequent appropriate use of health services for the prevention or early detection
of disease. It is also possible that the genetic counselling interaction itself will contribute to the possible use of preventative services.
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B A C K G R O U N D
Description of the condition
In 1963 an expert committee of the World Health Organisation
observed the importance of genetics in health by stating, “Ge-
netic considerations add a new dimension to public health work:
a concern not only for the health and well-being of persons now
living, but also for generations yet to come“ (WHO 2015). The
Council of Europe recommends that all countries develop a co-
herent and comprehensive national policy framework for genetic
services, making adequate genetic counselling available in an eq-
uitable manner (Council of Europe 2015). They state that, “the
development of genetics in health care services has a major impact
on the organisation of health care, leading to shifting from curative
to preventive services, from in-patient to out-patient treatment,
from specialised genetic services to genetics as an integral part of
general health services”.
Genetic and genomic technologies have the potential to provide
vital insight to support the accurate prevention, diagnosis and
treatment of disease (HGSG 2012). It is estimated that 5.5% of
the UK population will develop a genetic disorder by age 25, af-
fecting 2.8 million people (Genetic Alliance UK 2012). Patients
and families affected by rare diseases face lengthy delays in access-
ing a correct diagnosis. For example, almost half (46%, 221/481)
of patients in a UK survey had to wait over one year for a ﬁnal
diagnosis following the onset of disease symptoms (Rare Disease
UK 2011). Data from the 12,000 voices European survey of rare
diseases show that there are inequalities in access to genetic health-
care for diagnosis and on-going treatment (EURORDIS 2009).
Research has shown that social, environmental and economic con-
ditions may deter individuals or communities from accessing the
beneﬁts of these new technologies (WHO 2010; Burton 2011;
Genetic Alliance UK 2012; Bellcross 2013; Delikurt 2014).
Over the past 10 years genetic counselling has started to move
away from only being offered in genetic centres of excellence and
is now being accessed through new service delivery models. These
service deliverymodels involvemainstream clinical specialties such
as cancer or cardiac care (Burton 2011). Battista 2012 reviewed the
current organisation of genetic services in Europe, North America
and Australia and found that genetic counselling services relied
heavily on co-ordination of activities between professionals and
new ways of working required the reconﬁguration of professional
roles and responsibilities. Barriers to introducing new servicemod-
els included redistribution of roles, sharing of data and the lack of
preparedness of non-genetics professionals and healthcare systems
(Battista 2012). There is also evidence from professional surveys
that variation exists in models of service delivery within the same
country (Cohen 2013).
To date there have been few studies aimed at determining the ef-
fectiveness of interventions to help patients access genetic services.
The body of research evidence is developing rapidly and further
studies are currently ongoing or in the feasibility stage (Hodgson
2014). In order for patients and their families to beneﬁt from ge-
nomic advances they need to be identiﬁed, referred to and then
supported to use the services offered. This review is needed to
provide a benchmark of existing evidence and aims to describe
the effectiveness of interventions aimed at identifying potential
patients and enabling them to access and use genetic and genomic
counselling services.
Deﬁnitions
There remains confusion over how the terms ‘genetics’ and ‘ge-
nomics’ are used within studies and also by clinicians and scien-
tists. Until the late 1990s, most clinical services used the term
genetic services or medical genetics services. After this, the term
genomics was applied to some clinical services. The genome has
been described as ’an organism’s complete set of DNA, including
all of its genes and non-coding regions’ (Genetics Home Reference
2015). The following deﬁnitions reported by the UKNursing and
Midwifery task-force will be used for this review (Nursing and
Midwifery Council 2011).
Genetics
Genetics is the study of heredity and variation. In the healthcare
setting this has been associated with single gene and chromosomal
conditions traditionally managed by specialist genetics services.
Genomics
Genomics is the study of the structure and function of the genome,
including the interaction between genes and the environment.
Genomic healthcare
Genomic healthcare involves the use of genomic information and
technologies at any stage of the healthcare continuum to deter-
mine disease risk and predisposition, diagnosis and prognosis, and
the selection and prioritisation of therapeutic options. Genomic
healthcare also takes into account the potential ethical, psycholog-
ical and social implications of genomic information and the ap-
plication of genomic technologies. The term ’genomic healthcare’
incorporates the use of both genetic and genomic information and
technologies (Nursing and Midwifery Council 2011).
The process of genetic and genomic counselling
There are varying deﬁnitions of the process of genetic and genomic
counselling. This review will deﬁne the process of genetic and
genomic counselling using the deﬁnition provided by the United
States National Society of Genetic Counselors (Resta 2006).
“Genetic counseling is the process of helping people understand and
adapt to themedical, psychological and familial implications of genetic
contributions to disease. This process integrates the following:
• Interpretation of family and medical histories to assess the chance of
disease occurrence or recurrence.
• Education about inheritance, testing, management, prevention, re-
2Interventions to improve patient access to and utilisation of genetic and genomic counselling services. (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sources and research.
• Counseling to promote informed choices and adaptation to the risk
or condition”.
Genetic and genomic counselling services
This review will deﬁne the term genetic and genomic counselling
services as services that offer the process of genetic or genomic
counselling or both as part of service provision. In this review
genetic and genomic counselling services are broadly deﬁned as,
patient-facing products or services designed to support or inform
the patient regarding the risk of carrying, developing, or being
affected by health conditions which have a genetic or genomic
aetiology. Genetic and genomic healthcare services can consist of
both patient-facing and laboratory elements, employing a multi-
disciplinary workforce consisting of both clinical health profes-
sionals and laboratory scientists.
This review will include studies investigating the effectiveness of
interventions aimed at identifying potential patients and enabling
them to access genetic or genomic counselling services. These ser-
vices are available in most countries and patients have a right to
access them. However, there is great variation in how they are
organised, delivered and funded (WHO 2010; Trepanier 2014).
Increasingly, genetic and genomic counselling services are situ-
ated within other clinical specialties, such as a breast cancer fam-
ily history clinic operating as part of an oncology service (Burton
2011; Kirk 2014). This has been termed ‘mainstreaming’ of work
traditionally undertaken by genetic services or the use of genetic
knowledge within other clinical specialties. Services are adapting
to this challenge by developing new ways of working to meet the
demand for genetic and genomic counselling services (Eeles 2007;
Middleton 2014).
The genetic counselling interaction
This review is not aimed at determining the effectiveness of the
clinical genetic counselling interaction between the health profes-
sional and the patient. Interventions which solely target the pa-
tient’s psychological function or knowledge of the medical aspects
of their genetic condition will be excluded from this review. Inter-
ventions which target patient identiﬁcation, access to and use of
genetic and genomic services are the focus of this review. Usually
these activities occur prior to the genetic counselling interaction
event.
Health professionals who provide genetic counselling services
The professional role and training of clinical health professionals
providing the genetic counselling interaction vary. Health profes-
sionals undertaking genetic counselling include but are not lim-
ited to, medical clinical geneticists, genetic counsellors and ge-
netic nurses. In the United States there is a credentialing sys-
tem which regulates genetic nurses (ANCC 2015). In the United
States, Canada, Australasia, South Africa and the United King-
dom genetic counsellors have an established training, certiﬁcation,
and regulatory system (ABGC 2015; CAGC 2015; GCRB 2015;
HPCSA 2015). Across Europe, the European Board of Medical
Genetics have introduced a European genetic counsellor registra-
tion system for health professionals from a variety of backgrounds
(Skirton 2010).
For the purposes of this review, studies investigating genetic and
genomic counselling services which offer the process of genetic
counselling by a range of health professionals will be included.
When describing the effectiveness of the interventions included in
this review, mediating factors related to professional role, prepa-
ration and training will be considered when studies are reported
and acknowledged in the data analysis.
Description of the intervention
This review will include studies investigating a variety of interven-
tions that target patient identiﬁcation, access to and utilisation of
genetic and genomic services which provide genetic and genomic
counselling. Interventions that address these issues could be tar-
geted at the general population, health professionals (e.g. genetic
specialist or non-genetic specialist), clients of health professionals
or a combination of these.
Interventions could be categorised in a number of ways. We will
consider grouping interventions into those which aim to target po-
tential patients directly (e.g. publicity campaigns) and those which
target health professionals (e.g. clinical guidelines). Alternatively,
if appropriate within the above categories, we may categorise stud-
ies by the mode of delivery (e.g. printed or electronic guidelines)
or healthcare setting (e.g. primary, secondary or tertiary care).
Interventions could range from educational interventions (
Westwood 2012), to behaviour techniques to improve commu-
nication of test results to at-risk relatives (Hodgson 2014). Inter-
ventions may be targeted at the organisational level, such as doc-
tor or nurse role substitution (Torrance 2006). The interventions
included in this review will represent all those described by the
Cochrane Effective Practice and Organisation of Care (EPOC)
group taxonomy (EPOC 2002), and will include the following:
• Professional interventions - Those directed to professionals
to change their practice or behaviour;
• Financial interventions - These will include both health
provider and patient interventions;
• Organisational interventions - Including both health
provider and patient orientated interventions;
• Structural interventions - Including where services are
delivered; and
• Regulatory interventions - Including regulation or adoption
of certain genetic tests (EPOC 2002).
Table 1 shows the possible links between interventions, how these
interventions might work, based on the application of the theoret-
ical domains framework (Cane 2012); and the outcomes of inter-
est for this review which include improving identiﬁcation, access
to and use of genetic and genomic counselling services.
Table 1 - Linking interventions, possible behaviour change
modes of action and review outcomes
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Interventions to improve patient identiﬁcation, access and use of genetic and genomic counselling services
Description of interventions likely in genetic services Possible Mode of Action - based on the 14 categories of the
theoretical domains framework (Cane 2012)
Health professional attendance at educational workshops aimed
at increasing identiﬁcation of patients at genetic risk
• knowledge
• skills
• professional role
Reducing the cost of genetic tests to the health professional, patient
or organisation
• environmental context and resources
• social inﬂuences
• beliefs about consequences
Revision of professional roles, role substitution • environmental context and resources
• knowledge
• skills
• professional role
Change of where services are delivered (e.g. from specialist services
to primary care)
• knowledge
• skills
• professional role
• environmental context and resources
• social inﬂuences
Adoption of a genetic test by regulators (e.g. Preimplantation Ge-
netic Diagnosis for BRCA1)
• knowledge
• skills
• belief about capabilities
• belief about consequences
• social inﬂuences
How the intervention might work
Recognising which individuals are at increased genetic risk and
who would beneﬁt from access to genetic counselling services is
a key facilitator in patients actually utilising services (Delikurt
2014). Many of the interventions targeted at non-genetic health
professionals involve educational training and skills development
in order for them to recognise at risk individuals. Many health
professional organisations and policy groups have published com-
petency standards in genetics, however it is unclear if these have
improved patient identiﬁcation or access to services (Kirk 2003;
NCHPEG 2007; ANA 2009). Evidence in the medical education
literature show a number of theories relating to the success of de-
livery of continuing practice development with varied effects on
clinical patient care (Schostak 2010). Behaviour change interven-
tions, such as empowering patients to inform relatives who are at
genetic risk may facilitate patient access to services. If a study re-
ports a theoretical rational for the mechanism of the intervention,
this will be reported (Craig 2008). It is acknowledged by the the-
ory of planned behaviour that intention to perform a behaviour
could be a predictor of actual behaviour change. Therefore studies
targeting intention to perform certain behaviours as deﬁned in the
Primary outcomes section will be included in this review.
Other interventions, such as the introduction of clinical guide-
lines, or establishing clinical pathways which include referral to a
genetic counselling service, will be includedbut the success of these
interventions in other areas of healthcare is variable (Grimshaw
2004). This review will include any interventions targeting any
stage of the patient pathway from interventions which aim to
improve patient identiﬁcation, referral to or use of genetic and
genomic counselling services or those interventions which target
multiple elements (e.g. health professional educational sessions
might improve either identiﬁcation of at risk individuals or referral
or both). A service reorganisation might help improve access. It is
possible that some interventions may have the adverse effect of re-
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ducing appropriate referrals or deter patient utilization of services.
These outcomes, and any other adverse events reported in the in-
cluded studies, will be reported in the review. We will examine
study outcomes related to interventions which target the general
population, patients, health professionals or organisations.
Why it is important to do this review
Access to genetic services is seen as an essential part of the health
care system in most developed countries. However, there are only
two Cochrane reviews which address provision of care for genetic
conditions. Hilgart 2012 reviewed interventions which helped as-
sess risk in individuals already identiﬁed as at-risk for familial
breast cancer. Cox 2013 reviewed interventions promoting phys-
ical activity in patients with cystic ﬁbrosis. A review regarding the
effectiveness of preconception genetic risk assessment for a sub-
set of genetic conditions is currently ongoing (Hussein 2013).
The Delikurt 2014 systematic review of interventions aimed at
increasing patent access indicated a number of barriers to patient
referral among non-genetic health professionals including lack of
awareness of patient’s risk factors, failure to obtain adequate family
history, lack of knowledge of genetics and genetic conditions, lack
of awareness of genetic services, inadequate coordination of referral
and lack of genetics workforce. No reviews of the effectiveness of
interventions aimed at identifying patients, and enabling them to
access and use genetic and genomic counselling services have been
carried out.
O B J E C T I V E S
Primary objective
The primary objective is to assess the effectiveness of interventions
to improve patient identiﬁcation, access to and utilisation of ge-
netic and genomic counselling services when compared to:
i) No intervention;
ii) Usual or current practice; and
iii) Other active intervention.
Secondary objective
The secondary objective is to explore the resource use and costs
associated with interventions aimed at improving patient identi-
ﬁcation, access to and utilisation of genetic and genomic coun-
selling services from studies meeting the eligibility criteria.
We will report on factors that may explain variation in the effec-
tiveness of interventions aimed at improving patient identiﬁca-
tion, access to and utilisation of genetic and genomic counselling
services from studies meeting the eligibility criteria.
Another secondary objective is to explore how interventions which
target improved patient identiﬁcation, access to and utilisation
of genetic and genomic counselling services affect the subsequent
appropriate use of health services for the prevention or early de-
tection of disease. It is also possible that the genetic counselling
interaction itself will contribute to the possible use of preventative
services.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) and cluster-
RCTs comparing the intervention to usual practice, a control in-
tervention or other active intervention. In line with EPOC rec-
ommendations (EPOC 2015a), cluster-RCT studies will only be
eligible if there are at least two intervention sites and two control
sites. We will include studies regardless of language or publication
status (i.e. abstract, full text, unpublished data).
Types of participants
We will include studies of interventions targeted at the general
population, health professionals, health or social care organisations
or patients with the aim of improving patient identiﬁcation of,
access to and use of genetic and genomic counselling services in
primary, secondary and tertiary care service settings and those
transitioning between healthcare settings.
Participants will include:
• the general population;
• patients of all age groups (including but not limited to
genetic groupings, ’pre-natal’ or ’reproductive’, ’adult’, ’cancer’
and ’paediatrics’);
• health professionals including genetic and non-genetic
specialists; and
• organisations providing health or social care.
Eligible health professionals include, but are not limited to, doc-
tors, genetic counsellors, nurses, physiotherapists, pharmacists, oc-
cupational therapists, social workers, dieticians, psychologists, and
dentists if involved in the genetic counselling process. Genetic
specialists include consultant medical clinical geneticists, genetic
counsellors, or genetic nurse specialists. Studies aimed at multi-
disciplinary providers and organisations will also be included.
We will exclude studies directed at healthcare scientists involved
in non-patient facing services (e.g. the laboratory techniques of
genetic testing and studies with no patient facing contact such as
a change in laboratory techniques).
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Types of interventions
We will consider any intervention to improve potential patient
identiﬁcation, access to and utilisation of genetic and genomic
services as deﬁned in the Description of the condition section
compared to no intervention, usual care or practice or other active
intervention. These active interventions may include professional,
ﬁnancial, organisational, structural or regulatory interventions as
described in the EPOC taxonomy (EPOC 2002).
We will include studies of interventions that target the health be-
haviour of individuals such as patient utilisation of health services
outside genetic counselling services, health screening (e.g. mam-
mography or diabetes monitoring) and health management (e.g.
prophylactic surgery) only if the patient had previously accessed
genetic or genomic counselling services and were made aware of
an increased health or reproductive risk.We will include studies of
organisational interventions such as displays of leaﬂets and posters
or awareness campaigns.
We will include studies that involve a mixture of interventions. In
these situations outcomes will be reported if they are associated
with a speciﬁc type of intervention alone, otherwise theywill be re-
ported under the category of complex interventions. It is expected
that most interventions within the area of interest will be complex
interventions as described by theMedical ResearchCouncil (Craig
2008).
We will exclude studies if the intervention solely focuses on labo-
ratory processes or new technologies. However if the study aims to
assess the effectiveness of a complex interventionwhich is designed
to target the patient care pathway, and includes appropriate genetic
testing it will be included. We will also exclude studies where the
intervention is intended to identify potential patients, their access
to and use of somatic genetic testing (e.g. tumour testing to in-
form treatment), microbial genetics, applied infection genetics or
biomedical genetic testing not applied to healthcare. Interventions
which aim to target patient level psycho-educational outcomes,
such as improved education about the condition or decreased psy-
chological stress will be excluded if they are not assessed using one
of the primary outcome measures speciﬁed for this review.
Types of outcome measures
Primary outcomes
We will include studies that consider at least one of the ﬁve pri-
mary outcome measures listed in Table 2. We will include studies
that sought to measure one of the primary outcomes even if data
were not reported. Studies not targeting these outcomes will be
excluded.
Table 2 - Primary Outcomes of interest and examples of pos-
sible outcome measures
Primary outcome of interest Examples of possible outcome measures
1. Increased identiﬁcation of people who are at genetic risk or who
may beneﬁt from genetic or genomic counselling services
• Number or proportion of patients within a population
identiﬁed at increased risk
• Increased communication or intention to communicate
genetic risk to relatives
• Rate of health professional adherence to guidelines (e.g.
NICE familial breast cancer)
2. Increased access to genetic or genomic counselling services • Reduction in waiting times for clinic
• Number or proportion of referrals from primary care to
genetic or genomic counselling services
• Proportion of minority cultural and linguistic groups
within the population (e.g. black and ethnic minority groups, d/
Deaf individuals’)
3. Increased appropriate utilisation of genetic or genomic coun-
selling services
• Failure to attend rate for genetic or genomic counselling
services
• Uptake of genetic tests
4. Increased access to or use of other appropriate healthcare services
after genetic or genomic counselling services
• Referral rate and utilisation or intention to utilise
appropriate evidence based mammography screening
• Actual compliance or intention to engage with appropriate
preventative health service, such as diabetes management
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(Continued)
5. Resource use and costs • Out of pocket patient costs
• Direct healthcare resource
Secondary outcomes
We will consider any adverse events and the equity outcomes re-
ported in the included studies as secondary outcomes. We will use
an ’equity lens’ to determine how factors associated with disad-
vantage (social stratiﬁcation) might interact with the hypothesised
mechanisms of action of the intervention (Uefﬁng 2012; Tugwell
2010). We will exclude studies that only report on secondary out-
comes.
Search methods for identification of studies
Electronic searches
In consultation with the authors, the EPOC trials search coordi-
nator drafted a sensitive search strategy designed to retrieve studies
from electronic bibliographic databases. We will search the follow-
ing databases:
• MEDLINE via OVID (1946 to July 2015);
• Cochrane Library via Wiley (Issue 7, 2015) including
CENTRAL;
• Database of Reviews of Effects (DARE);
• Health Technology Assessment database (HTA);
• EMBASE via OVID (1947 to July 2015);
• CINAHL via Ebsco (1980 to July 2015);
• PSYCINFO via OVID (1867 to July 2015);
• Genetics Abstracts via Proquest (1990 to July 2015); and
• Pubmed related articles search of key papers.
The searches for this review will be developed and carried out in
accordance with current guidance from the Cochrane Collabora-
tion (MECIR 2013). The Cochrane RCT Sensitivity and Preci-
sionMaximising Filter (Lefebvre 2011), will be used for theMED-
LINE and EMBASE searches. We will not apply any study de-
sign ﬁlters to the other database searches. We will not apply any
restrictions based on language, publication type, or publication
year. The search strategy will be devised for theOVIDMEDLINE
interface and then adapted for the other databases.
The MEDLINE search strategy is reported in Appendix 1
We will also search for economic studies using the NHS CRD
economics search ﬁlter (CRD 2014). This search will be used to
identify published economic evaluations and cost analysesmeeting
the primary objectives and inclusion criteria for the review.
We will pool all titles and abstracts and delete duplicates.
Searching other resources
We will search the reference lists of the included studies and any
relevant systematic reviews to identify additional studies. Relevant
individuals and organisations will be consulted for information
about unpublished or ongoing studies. We will search the clini-
caltrials.gov study register to identify ongoing studies.
Data collection and analysis
Selection of studies
The titles and abstracts of the studies identiﬁed by the literature
search will be independently screened by two members of the re-
view team to assess which studies meet the inclusion criteria. One
screener will be a review author (CB, JC, LT, HS, KC, SG, RB).
Next, we will retrieve full-text copies of all potentially relevant pa-
pers and these studies will be independently assessed by two review
authors (CB, JC, LT, HS, CP, KC, SG, RB) to assess eligibility.
Disagreements will be resolved through discussion and consensus
or by input from a third review author as necessary.
Wewill report data on the number of retrieved references, the num-
ber of obtained full-text papers and the number of included and ex-
cluded studies based on the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis (PRISMA) ﬂowchart guidelines
and include a ’Characteristics of Excluded Studies’ table (Moher
2009). Studies will be managed in Endnote X7 (Endnote 2014),
and Review Manager (Review Manager 2014).
Data extraction and management
Twoauthors (CB, JC, LT,HS,CP,KC, SG,RB)will independently
extract data using a standardised data extraction sheet (Appendix
2), based on the generic EPOC data collection checklist (EPOC
2015b), including:
• Mode of delivery e.g. one-to-one face to face or group based
face to face or web-based face to face sessions or web-based self
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study (video/ DVD); type of health professional delivering the
intervention (e.g. doctor or genetic counsellor);
• Setting and process e.g. primary care or secondary care; du-
ration of intervention (including length and number of sessions
and period over which intervention delivered); incentives or reim-
bursement of staff;
• Theoretical basis classiﬁed using the 14 categories of the Theo-
retical Domains Framework (Cane 2012), and deﬁned by Michie
2010 and Michie 2013; and
• Content e.g. genetic counselling or genetic information giv-
ing, family history awareness, risk assessment, psychosocial sup-
port, family communication, health behaviour change manage-
ment, screening advice, access to genetic testing, interpretation of
genetic tests.
Data will be extracted directly from study reports. Before investi-
gating whether data can be standardized across studies (e.g. num-
ber of patients identiﬁed per 100,000 population), we will report
data in natural units as reported by the investigators. Any unre-
solved differences in data extraction will be referred to a third au-
thor. Where necessary additional information will be sought from
the authors of the primary studies. All relevant data will be entered
into the RevMan5 software (Review Manager 2014).
We will collect contextual data to consider if any characteristics of
the populations (including settings and contexts) could be used as
explanatory factors. This is described further in the Assessment of
heterogeneity section.
We will identify studies that have reported collecting primary re-
source use and cost data and summarise these studies in terms of
interventions, study population, including the relevant country
for the analysis; study perspective, time horizon, method used to
identify resource use data, method used to identify cost use data;
method used to assimilate resource use and cost data, key ﬁndings,
key uncertainties and limitations of the analysis. Economic studies
will be classiﬁed as full economic evaluations (e.g. cost effective-
ness analysis, cost utility analysis or cost beneﬁt analysis) or partial
evaluation studies (e.g. costminimisation analysis or cost analysis).
Within this classiﬁcation, we will summarise model, observational
and trial-based studies that have identiﬁed primary resource use
and cost data.
Assessment of risk of bias in included studies
Two review authors (CB, JC, CP, LT) will independently assess the
risk of bias for all eligible studies using the criteria described in the
EPOC group resources for review authors. The risk of bias will be
assessed using the Cochrane risk of bias tool (Higgins 2011a), and
in accordance with the EPOC group’s ‘Guidance on Risk of Bias’
(EPOC 2013a). We will compare results and resolve discrepancies
by discussion and consensus.
The EPOC group’s guidance on assessing risk of bias consists of
nine criteria for all RCTs:
• Was the allocation sequence adequately generated?;
• Was the allocation adequately concealed?;
• Were baseline outcome measurements similar?;
• Were baseline characteristics similar?;
• Was the study adequately protected against contamination?;
• Were incomplete outcome data adequately assessed?;
• Was knowledge of the allocated interventions adequately
prevented during the study?;
• Was the study free from selective outcome reporting?; and
• Was the study free from other risk of bias?
The results will be reported in a ’risk of bias’ table.
We will summarise the overall risk of bias for each study (across
outcomes) and for each outcome or class of similar outcomes
(across studies) using the following criteria (EPOC 2013a;Higgins
2011a):
• Within each study across domains:
◦ Studies with low risk of bias for all key domains or
where it seems unlikely for bias to seriously alter the results will
be considered to have a low risk of bias;
◦ studies where risk of bias in at least one domain was
unclear or judged to have some bias that could plausibly raise
doubts about the conclusions will be considered to have an
unclear risk of bias; and
◦ studies with a high risk of bias in at least one domain
or judged to have serious bias that decreases the certainty of the
conclusions will be considered to have a high risk of bias.
• Across studies:
◦ each outcome (or class of outcomes) will be deﬁned as
having a ’low risk of bias’ if most information is from studies at
low risk of bias;
◦ as ’high risk of bias’ if the proportion of information
from studies at high risk of bias is sufﬁcient to affect the
interpretation of the results; and
◦ an ’unclear risk of bias’ if most information is from
studies at low or unclear risk of bias.
It is likely for this review that study participants will not be blinded
for some interventions (e.g. delivery of an educational interven-
tion). This will be noted in the quality assessment.
Measures of treatment effect
Many of the outcome measures for this review consist of discrete
quantitative data (e.g. numbers of patients gaining access to ser-
vices). For continuous outcomes we will calculate the mean dif-
ference (MD) and corresponding 95% conﬁdence interval (95%
CI). If the numbers of participants and events are available for di-
chotomous outcomes (e.g. referral made yes/no), we will calculate
the risk ratio (RR) or odds ratio (OR) and corresponding 95% CI.
If effect estimates (RR or OR) are reported instead of proportions
these will be extracted accompanied by measures of uncertainty
(e.g. 95% CI or P value if available).
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Unit of analysis issues
Consideration will be given to whether any unit of analysis errors
are made in the reported analysis for a study. For example, for
cluster-randomised trials we will consider whether the reported
results are on the same level as the level of allocation or whether an
analysis is adjusted for clustering effect. If a unit-of-analysis issue
is identiﬁed, the treatment of the study will depend on the type of
design and on the available information. Depending on the study,
one of the following methods of avoiding unit of analysis issues
will be accepted: re-analyse the data if information is sufﬁcient; if
there is insufﬁcient information to re-analyse the results the study
authors will be contacted to obtain necessary data; if data are not
available results of the analysis will be reported in the review in
the form of estimates without reporting a measure of uncertainty.
Dealing with missing data
Authors will be contacted if data are missing from the published
papers. If missing data are still present then each case will be dis-
cussed to determine themost appropriate analysis strategy.We will
either report the results based on observed data or use imputation
for appropriate types of continuous data (e.g. using the standard
error to calculate missing standard deviations).
Assessment of heterogeneity
It is likely that the included studies may show both statistical and
contextual heterogeneity. Contextual heterogeneity may include:
a range of measured outcomes, differing health systems or health
economies, and a wide range of diagnoses and patient populations.
We will assess contextual differences by examining these factors.
It is possible that due to lack of suitable studies there may not be
enough data to draw ﬁrm conclusions about the overall effective-
ness of an intervention. In addition, there may not be enough data
to perform sub-group analysis. In this case we will specify explana-
tory factors and, if possible, use these factors to guide discussion
of the applicability of the ﬁndings. Possible explanatory ﬁndings
might include:
• Differences between insurance based or free point of use
services;
• Interventions delivered by non-genetic specialists or genetic
specialist health professionals;
• Differences between patient target groups (e.g. pre-natal,
adult, cancer or paediatric);
• Intervention setting (e.g. primary care or specialist service);
and
• Socioeconomic status of participants.
Information relating to context will be collected and reviewed
against the results obtained. It is likely that these factors will help
with the interpretation of the results and form part of a narrative
description in the ﬁnal review. The context surrounding the study
is important in assessing the effectiveness of the intervention and
the overall provision of genetic counselling services. Context will
also be important when developing the summary of ﬁndings tables
(See Data synthesis).
Assessment of reporting biases
If there are a sufﬁcient number of pooled studies (i.e. > 10), we
will assess reporting bias by visual inspection of funnel plots.
Data synthesis
Due to heterogeneity in service provision and study design, we
expect to ﬁnd variation across studies in follow-up periods and
outcomes.We will report study outcomes irrespective of the range,
timing and follow-up periods for the study or how the outcomes
were measured. This will minimise selective outcome reporting.
Data synthesis will use a range of effects and plain language sum-
maries following the GRADE guidelines (EPOC 2015c). The re-
sults will be presented in a summary of ﬁndings table (EPOC
2015c; Higgins 2011b) and make qualitative assessment of the
effects of the studies - based on quality, size and direction of effect
observed and statistical signiﬁcance. We will pool data for meta-
analysis when studies are reasonably similar in terms of popula-
tions, interventions,
characteristics, and outcomes. For dichotomous outcomes, we will
calculate the pooled RR or OR and corresponding 95% CI. For
continuous outcomes we will calculate the pooled MD and cor-
responding 95% CI. We will calculate the standardized mean dif-
ference (SMD) and corresponding 95% CI when studies utilise
different scales to measure the same underlying construct. A ﬁxed-
effect model will be used to pool data unless signiﬁcant hetero-
geneity is identiﬁed.
Wewill report the following data where available: pre-intervention
and post-intervention study outcome in natural units, statistical
signiﬁcance across groups, and variability of outcome.
Resource use will be considered for inclusion in a Summary of
Findings (EPOC 2015c), table and a brief economic summary
will form part of the review (EPOC 2013c).
Subgroup analysis and investigation of heterogeneity
We will assess statistical heterogeneity by both a visual inspection
of forest plots and by calculating the Chi2 and I2 statistics. We
would consider an I2 value of greater than 60% as evidence of
substantial heterogeneity of a magnitude where statistical pooling
is not appropriate. We will use a random-effects model to pool
data in situations where there is moderate heterogeneity (e.g. I2 is
less than 60% but more than 25%).
Data synthesis will be structured as recommended by EPOC
guidelines (EPOC 2013b). If there are sufﬁcient studies of similar
interventions it might be possible to perform a sub-group analysis.
Potential subgroup analyses could include:
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• Healthcare setting (e.g. primary care or specialised hospital
services);
• Who delivers the intervention (e.g. educator or health
professional);
• Disadvantaged or advantaged population (e.g. lower
socioeconomic groups);
• Ethnicity (e.g. general populations versus minority groups);
and
• Income status of the country (e.g. low and middle income
countries versus high-income countries).
The above factors could be used to guide discussion around the
applicability of the ﬁndings. Data extraction will include these key
explanatory factors (see Data collection and analysis).
Sensitivity analysis
We will explore the robustness of the results by conducting sensi-
tivity analysis based on:
1. Excluding studies assessed as being at high risk of bias;
2. Excluding studies with missing or imputed data; and
3. Calculating a random-effects model.
Where appropriate, sensitivity analysis will be performed to assess
the robustness of conclusions and results will be presented in a
summary table. If review results are sensitive to particular assump-
tions (e.g. study quality) this will be investigated and reported in
the review. We will also use sensitivity analysis as appropriate to
explore potential explanations for heterogeneity (e.g. by excluding
obvious outlier studies).
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
Search Strategy:
--------------------------------------------------------------------------------
1 exp Genetic Counseling/ (11904)
2 exp Genetic testing/ (27106)
3 exp Genetic predisposition to disease/ (94167)
4 ((risk$ or gene$ or geno$) adj3 (service$ or screen$ or inform$ or counsel$ or test$)).tw. (152697)
5 or/1-4 (255462)
6 delivery of health care, integrated/ (8702)
7 exp health services/ (1610829)
8 exp “Referral and Consultation”/ (57906)
9 exp patient-centered care/ (11588)
10 exp health services accessibility/ (85233)
11 (service$ adj3 organi$).tw. (5702)
12 (multi-disciplin$ or multidisciplin$).tw. (51388)
13 “Delivery of Health Care”/ (66464)
14 or/6-13 (1775488)
15 5 and 14 (56030)
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16 (randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or ran-
domly.ab. or trial.ti. (935973)
17 exp animals/ not humans.sh. (3986356)
18 16 not 17 [Cochrane RCT Filter 6.4.d Sens/Precision Maximizing] (863154)
19 15 and 18 (2845)
Appendix 2. Data Extraction Form
Interventions to improve patient access to and utilisation of genetic and genomic counselling services.
Data extraction and management - Draft data extraction sheet
• Country where research was carried out
• Study inclusion and exclusion criteria
• Study design (e.g. RCT, cluster-RCT)
• Recruitment method (e.g. self referral, advertisement)
• Target population
◦ Condition (e.g. breast cancer, cystic ﬁbrosis, all conditions)
◦ Group Category (e.g. prenatal, paediatric, cancer or adult (non-cancer)
◦ Risk Category (e.g. low, medium, high, mixed)
◦ Ethnicity (e.g. Ashkenazi Jewish)
◦ Setting (e.g. population, primary care, secondary care, genetic patients)
◦ Socioeconomic (e.g. low or middle income or high economic population)
• Study intervention healthcare setting (e.g. primary care, specialised services)
• Description of usual care
• Intervention details
◦ Mode of delivery
◦ Setting and process
◦ Theoretical basis (e.g. using 93-item BCT taxonomy (Michie 2013) or educational theory)
◦ Content
◦ Intervention target (e.g. healthcare staff or clients or both),
◦ Behavioural target (e.g. communication with family members; utilisation of healthcare services, genetic service, genetic
testing, or screening services);
◦ Health condition targeted (e.g. diabetes, breast cancer, mixed)
• Healthcare worker details
◦ Professional group
◦ Qualiﬁcation level
◦ Job title
◦ Number
◦ Age
◦ Socioeconomic status
◦ Ethnicity
◦ Gender
◦ Time since qualiﬁcation
• Client/Patient details: number, age, socioeconomic status, ethnicity, gender, time since diagnosis (where applicable)
• Other outcomes measured by the study
• Quality criteria (in line with EPOC recommendations (EPOC 2015b) and EPOC Guidance on risk of bias (EPOC 2013a))
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